ACAAI Tag

06 Dec

Posted at 02:33h in Allergies, Author Interviews, Dermatology
[caption id="attachment_71677" align="alignleft" width="200"]Dr. Shaila Gogate, MDColorado Allergy & Asthma Centers Allergist REMIX-1/-2 Investigator  Dr. Gogate[/caption] MedicalResearch.com Interview with: Dr. Shaila Gogate, MD Colorado Allergy & Asthma Centers Allergist REMIX-1/-2 Investigator MedicalResearch.com: What is the background for this study? What are the main findings? A: The Phase III REMIX-1/-2 studies were randomized, double-blind, placebo-controlled studies assessing the efficacy and safety of oral  remibrutinib 25 mg twice daily or placebo over a 24-week double-blind period, followed by a 28-week open-label remibrutinib treatment period. The purpose of this pooled analysis was to examine the early and long-term efficacy data of remibrutinib vs. placebo over time, looking at the mean percentage change from baseline (CFB) in weekly scores of disease activity (UAS7), itch severity (ISS7) and hives severity (HSS7) over 52 weeks. This analysis demonstrated that remibrutinib showed reductions in urticaria symptoms vs. placebo as early as week 1:
    • 38.4% vs. 10.3% in UAS7
    • 37.0% vs. 9.8% in ISS7
    • 39.8% vs. 10.1% HSS7 Greater reductions vs. placebo were seen over 24 weeks and results were observed in the open-label period through week 52 in all remibrutinib-treated patients (including those transitioned from placebo).

05 Dec

Posted at 18:41h in Allergies, Author Interviews, Dermatology
MedicalResearch.com Interview with: [caption id="attachment_71671" align="alignleft" width="133"]Dr. Giselle Mosnaim MD MSAllergist Division of Allergy and Immunology Department of Medicine Northshore University Health System REMIX-1/-2 Investigator Dr. Mosnaim[/caption] Dr. Giselle Mosnaim MD MS FACAAI Allergist Division of Allergy and Immunology Department of Medicine Northshore University Health System REMIX-1/-2 Investigator MedicalResearch.com: What is the background for this study? What are the main findings? Response: Chronic spontaneous urticaria is a debilitating condition significantly affecting patient quality of life and is characterized by the presence of itch, hives, and/or angioedema (swelling) lasting for greater than 6 weeks, without identifiable trigger. Second-generation H1-antihistamines at standard doses are recommended as first-line treatment for patients with chronic spontaneous urticaria, and can be up-dosed to 4 times the standard dose. However, over 50% of patients continue to have symptoms despite this therapy. Both Remibrutinib and Dupilumab are FDA-approved for the treatment of chronic spontaneous urticaria in adult patients (Remibrutinib ≥ 18 years old and Dupilumab ≥ 12 years old) who remain symptomatic despite second-generation H1-antihistamine treatment. The RECLAIM study is an ongoing head-to-head randomized controlled trial comparing the efficacy of Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, and Dupilumab, an injectable anti-interleukin-4 and anti-interleukin-13 inhibitor, at early timepoints (4 weeks and earlier) when administered as an add-on therapy in adults with moderate to severe chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines.

15 Nov

Posted at 12:31h in Allergies, Author Interviews
MedicalResearch.com Interview with: [caption id="attachment_51998" align="alignleft" width="189"]Christopher M. Bland, Pharm.D., FCCP, FIDSA, BCPS Clinical Associate Professor Clinical and Administrative Pharmacy University of Georgia College of Pharmacy Clinical Pharmacy Specialist St. Joseph’s/Candler Health System Savannah, GA  Dr. Bland[/caption] Christopher M. Bland, Pharm.D., FCCP, FIDSA, BCPS Clinical Associate Professor Clinical and Administrative Pharmacy University of Georgia College of Pharmacy Clinical Pharmacy Specialist St. Joseph’s/Candler Health System Savannah, GA MedicalResearch.com: What is the background for this study? Response: Nearly 10% of the United States population self-report a penicillin allergy. However 90% of these allergies are found to be false upon reconciliation which includes patient interview, graded challenge, direct challenge, or penicillin skin testing. This is crucial as patients labeled with a penicillin allergy often receive more expensive antibiotics that additionally cause more adverse effects. While reconciling penicillin allergies is an important antimicrobial stewardship goal, resources are often limited in various healthcare settings to accomplish several of these endeavors. Our study evaluated the use of pharmacy students to serve as patient interviewers to aid in reconciling penicillin allergies.

13 Nov

Posted at 22:59h in Allergies, Author Interviews, Cancer Research, Pediatrics
MedicalResearch.com Interview with: [caption id="attachment_52106" align="alignleft" width="200"]Sairaman Nagarajan, MD Clinical Fellow at State University New York (SUNY) Downstate Medical Center College of Medicine Dr. Nagarajan[/caption] Sairaman Nagarajan, MD Clinical Fellow at State University New York (SUNY) Downstate Medical Center College of Medicine MedicalResearch.com: What is the background for this study? Response: The impetus for this study came from our previous research linking asthma, hay-fever and overall cancer diagnoses using the CDC’s National Health Interview Survey database. The division of Allergy and Immunology at SUNY Downstate has also conducted two pilot studies on the relationship between parental cancer and childhood asthma in Brooklyn’s population; one from Lutheran Medical Center focusing on Hispanics and Asian patients, and the other on African-American and Afro-Caribbean patients.

13 Nov

Posted at 01:53h in Allergies, Author Interviews, Electronic Records
MedicalResearch.com Interview with: Sonam Sani MD Allergy & Immunology Fellow NYU Winthrop Hospital MedicalResearch.com: What is the background for this study? Response: Penicillin allergy label removal is becoming more common. Studies have shown that while 10% of the general population report an allergy to penicillin, after testing only 1% truly have an allergy. Allergists have the ability to evaluate patient’s for penicillin allergy by performing skin tests and oral challenges. However, even when people test negative for penicillin allergy, they still face barriers to having the label removed. We are noting more and more that despite having negative testing, upon further encounters, our patients still have their penicillin allergy label.